Thursday, December 06, 2001
Paul Lucas, President and CEO of GlaxoSmithKline Inc., is pleased to announce the appointment of John Vavricka as Vice President of Marketing.
Mr. Vavricka will lead the team managing GlaxoSmithKline’s extensive and diverse product portfolio which includes Paxil® for depression, Flovent® and Advair® for asthma, and Avandia® for type 2 diabetes.
Mr. Vavricka has 14 years of experience in the pharmaceutical industry, where he has demonstrated strong leadership qualities and held senior positions in both Marketing and Sales.
Prior to joining GlaxoSmithKline in Canada, Mr. Vavricka was the Vice President, Global Product Strategy Cardiovascular and Urogential Therapeutic Areas. Before returning to Marketing Mr. Vavricka was a Regional Vice President of Sales in the US for two years.
Mr. Vavricka’s educational background includes a Bachelor of Arts in Neurobiology and Physiology from Northwestern University in Evanston, Illinois.
GlaxoSmithKline is one of the world's leading researchbased pharmaceutical and healthcare companies. In Canada, GlaxoSmithKline employs more than 1,800 people and is one of the top 20 contributors to Canadian Research and Development.
Back to top